The 3q25 rs2305619 Polymorphism Associates With Microvascular Obstruction in STEMI

Indonesian Cardiovascular Research Center

Status: Completed

Conditions: Microvascular Coronary Artery Disease; STEMI

Treatments: Other: Long pentraxin 3

Study type: Observational

Funder types: Other

Identifiers

NCT03907722

IndonesianCRC2

Details and patient eligibility

About

The investigators enrolled 217 patients with acute STEMI undergoing primary PCI. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.

Full description

The investigators enrolled 217 patients with acute STEMI undergoing primary PCI in a tertiary care academic cardiovascular center. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit. The primary outcome of the study was the incidence of coronary microvascular obstruction defined as thrombolysis in myocardial infarction (TIMI) grade <3 flow after primary PCI or TIMI grade 3 flow with myocardial blush grade 0 or 1. Patients were grouped based on the genotypic variants (AA, AG and GG). The primary outcome was compared among the three variants, as well as the PTX3 concentration and 30-day mortality.

Enrollment: 217 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with acute STEMI with symptom onset <12 h and treated by primary PCI

Exclusion criteria

• STEMI patients who received fibrinolytic therapy

Trial design

217 participants in 1 patient group

Genotypic variants

Description:

AA, AG and GG genotype

Treatment:

Other: Long pentraxin 3